The Impact of Hepatitis C Virus Infection on Buprenorphine Dose in Pregnancy.

Abstract

OBJECTIVE\n\u2003Buprenorphine (BUP) is commonly used for opioid maintenance therapy in pregnancy. Our goal was to determine whether liver dysfunction related to hepatitis C virus (HCV) infection impacts BUP dosing requirements in pregnancy.\n\n\nSTUDY DESIGN\n\u2003This was a retrospective cohort study of pregnant women with antenatal exposure to BUP to compare dosing between individuals positive versus negative for HCV infection. Spearman correlation tests were used to assess the relationship between BUP dose and HCV status.\n\n\nRESULTS\n\u2003HCV infection was present in 103 (39%) of the patients. Patients with HCV infection required lower dose increases of BUP throughout pregnancy (p\u2009=\u20090.02). HCV viral load was positively correlated with the liver enzymes aspartate transaminase (r\u2009=\u20090.30, p\u2009=\u20090.003) and alanine transaminase (r\u2009=\u20090.25, p\u2009=\u20090.01). There was a negative correlation between HCV viral load and BUP dose during the second trimester (r\u2009=\u2009-0.27, p\u2009=\u20090.01) and third trimester (r\u2009=\u2009-0.20, p\u2009=\u20090.04).\n\n\nCONCLUSION\n\u2003Women with HCV infection required less of an increase in BUP dose throughout pregnancy compared with women without HCV infection. Severity of HCV infection, as measured by viral load and liver enzymes, was also associated with BUP dosing.